MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Integra LifeSciences Holdings Corporation General and Administrative Expenses 2011-2026 | IART
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Integra LifeSciences Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 717 M | 657 M | 616 M | 637 M | 595 M | 688 M | 691 M | 624 M | 456 M | 416 M | 446 M | 394 M | 373 M | 358 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 717 M | 358 M | 548 M |
Quarterly General and Administrative Expenses Integra LifeSciences Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 M | 181 M | 177 M | 195 M | 166 M | 162 M | 165 M | 167 M | - | 144 M | 161 M | 160 M | - | 156 M | 163 M | 157 M | - | 150 M | 116 M | 166 M | - | 173 M | 165 M | 175 M | - | 173 M | 177 M | 164 M | - | 146 M | 145 M | 142 M | - | 112 M | 119 M | 112 M | - | 113 M | 99.3 M | 93.3 M | - | 93.8 M | 115 M | 108 M | - | 99.8 M | 103 M | 103 M | - | 93.1 M | 96.1 M | 87.4 M | - | 87.5 M | 95.7 M | 80.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 80.1 M | 137 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
16.5 M | $ 9.23 | -1.6 % | $ 261 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | USA |
 |
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.46 | - | $ 130 M |  France |
 |
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
382 M | $ 12.07 | - | $ 1.63 B | USA |
 |
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | USA |
 |
FONAR Corporation
FONR
|
23.5 M | $ 18.6 | - | $ 122 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
894 M | $ 36.66 | -0.22 % | $ 5.46 K | USA |
 |
Globus Medical
GMED
|
1.18 B | $ 90.0 | 1.58 % | $ 12.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
9.27 M | $ 1.81 | -4.74 % | $ 1.1 M | USA |
 |
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | USA |
 |
Inspire Medical Systems
INSP
|
625 M | $ 54.21 | 0.13 % | $ 1.59 B | USA |
 |
Integer Holdings Corporation
ITGR
|
212 M | $ 85.77 | 0.16 % | $ 2.98 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.78 | -1.0 % | $ 370 M | USA |
 |
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.01 | 1.85 % | $ 17.1 M | USA |
 |
LENSAR
LNSR
|
45.2 M | $ 5.82 | -1.27 % | $ 69.6 M | USA |
 |
Medtronic PLC
MDT
|
10.8 B | $ 86.12 | -0.19 % | $ 111 B | USA |
 |
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | USA |
 |
Myomo
MYO
|
14 M | $ 0.67 | -4.9 % | $ 28 M | USA |
 |
Align Technology
ALGN
|
1.76 B | $ 167.26 | -2.69 % | $ 12.5 B | USA |
 |
AxoGen
AXGN
|
44.6 M | $ 31.33 | -4.03 % | $ 1.44 B | USA |
 |
Orthofix Medical
OFIX
|
554 M | $ 11.58 | -1.61 % | $ 459 M |  Curacao |
 |
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Penumbra
PEN
|
663 M | $ 329.2 | -0.2 % | $ 12.8 B | USA |
 |
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | USA |
 |
Insulet Corporation
PODD
|
1.16 B | $ 203.09 | -0.2 % | $ 14.3 B | USA |
 |
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M |  Canada |
 |
Sintx Technologies
SINT
|
6.2 M | $ 2.49 | -1.58 % | $ 6.91 M | USA |
 |
Butterfly Network
BFLY
|
39.8 M | $ 4.03 | -2.42 % | $ 853 M | USA |
 |
Smith & Nephew plc
SNN
|
2.72 B | $ 31.88 | -2.3 % | $ 23.8 B |  Britain |
 |
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
8.65 B | $ 331.18 | -0.34 % | $ 127 B | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.59 | 0.69 % | $ 36.7 M | USA |
 |
Tactile Systems Technology
TCMD
|
88.7 M | $ 24.49 | -0.33 % | $ 560 M | USA |
 |
TELA Bio
TELA
|
15.7 M | $ 0.62 | -2.08 % | $ 29.1 M | USA |
 |
TransMedics Group
TMDX
|
185 M | $ 104.84 | 0.04 % | $ 3.56 B | USA |
 |
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | USA |
 |
Tandem Diabetes Care
TNDM
|
445 M | $ 19.55 | 1.98 % | $ 1.33 B | USA |
 |
Delcath Systems
DCTH
|
43.5 M | $ 9.61 | -0.98 % | $ 344 M | USA |
 |
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.89 B | $ 61.27 | -2.11 % | $ 90.7 B | USA |